Overall impact
D (31)

Commentary

Inotiv is a below-average overall performer. With a 'D' rating of 30.9 for overall impact (bottom 25% of all companies), Inotiv ranks 102nd out of 112 industry peers, behind GXP Engaged, Bureau Veritas, CohnReznick and 98 others, and ahead of Young & Associates, Caci International, Agility Recovery and 7 others. On top material causes for Inotiv's industry (Professional Services), Inotiv performs poorly in Accountable Institutions (0.0 score), Free, Secure Flow of Information (4.0), Decent, Safe Work Opportunities (29.7) and 17 other causes where it received a 'D' or 'F' score. Inotiv did not receive an 'A' rating on any cause.
Impact
Cause NOTV
Peer rank
Overall impact

Log in to view this information

Impact trend

Change in rating for overall impact

Log in to view this information

Company
Employees
1,945
Sector
Industrials
Industry
Professional Services
Sub-industry
Research & Consulting Services
SASB industry
Professional & Commercial Services
Headquarters
In, United States
Share classes
NOTV
Description
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. It operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DSA segment manufactures scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the company's BASi product line. The RMS segment engages in commercial production and sales of research models, diets, bedding, and bioproducts. The company was formerly known as Bioanalytical Systems, Inc. and changed its name to Inotiv, Inc. in March 2021. Inotiv, Inc. was incorporated in 1974 and is headquartered in West Lafayette, Indiana.
Material causes
Ethos considers the following causes material for Inotiv, based on its industry sub-industry Research & Consulting Services. Learn more about material causes in our methodology overview.

This information is subject to Ethos' Terms and Conditions, which you can find here.

This information may not be used for corporate financing purposes (including, without limitation, ESG-linked loans, credit facilities, securities or structured products), as a basis for any financial instruments or products (including, without limitation, passively managed funds and index-linked derivative securities) or other products or services, to verify or correct data in any other compilation of data or index, to create any derivative works, nor to create any other data or index (custom or otherwise), without Ethos' prior written permission.

By browsing this site you agree to our use of cookies. Read more.
We use cookies on this site to enhance your user experience. By continuing to browse the site, you are agreeing to our use of cookies. Give me more info.